InflaRx
Yahoo Finance • 13 days ago
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received... Full story
Yahoo Finance • 27 days ago
Top movers analysis one hour before the close of the markets on 2025-08-29: top gainers and losers in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GMHS... Full story
Yahoo Finance • 27 days ago
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GMHS [https://www.chartmill.com/stock/quote/GMHS/profile] 93.89%... Full story
Yahoo Finance • last month
InflaRx Announces Participation in September Investor Conferences
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor c... Full story
Yahoo Finance • 2 months ago
InflaRx reports Q2 results
* InflaRx press release [https://seekingalpha.com/pr/20192936-inflarx-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:IFRX [https://seekingalpha.com/symbol/IFRX]): Q2 For the six months ended June 30,... Full story
Yahoo Finance • 2 months ago
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody... Full story
Yahoo Finance • 2 months ago
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its seco... Full story
Yahoo Finance • 2 months ago
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule
* InflaRx N.V. (NASDAQ:IFRX [https://seekingalpha.com/symbol/IFRX]) received a Nasdaq notice for falling below the $1 minimum bid price for 30 consecutive business days. * The company has 180 calendar days, until January 7, 2026, to re... Full story
Yahoo Finance • 2 months ago
InflaRx receives nasdaq notice for minimum bid price requirement
JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), currently trading at $0.88 with a market capitalization of ~$61 million, has received a written notice from Nasdaq indicating that the company’s share price has fallen below the minimum $1.00 per... Full story
Yahoo Finance • 2 months ago
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice... Full story
Yahoo Finance • 4 months ago
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Comm... Full story
Yahoo Finance • 4 months ago
InflaRx to Participate in Upcoming Investor Conferences
JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in m... Full story
Yahoo Finance • 5 months ago
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company... Full story
Yahoo Finance • 6 months ago
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenos... Full story
Yahoo Finance • 7 months ago
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its fin... Full story
Yahoo Finance • 7 months ago
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed it... Full story
Yahoo Finance • 7 months ago
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its under... Full story
Yahoo Finance • 7 months ago
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an... Full story
Yahoo Finance • 8 months ago
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Gugge... Full story
Yahoo Finance • 2 years ago
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that... Full story
